Patent ID: 9211312
Filing Date: 2015-12-15
Classification: A61K,A61P

Abstract:
1. A method of treating or preventing a post-infective demyelinating polyradiculoneuropathy (Guillain Barré syndrome) comprising administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that binds complement C5, wherein the agent that binds C5 is: a) a protein comprising or consisting of amino acids 19 to 168 of the amino acid sequence of SEQ ID NO: 2; b) a protein comprising or consisting of amino acids 1 to 168 of the amino acid sequence of SEQ ID NO: 2; c) a protein of (a) or (b) having at least 95% sequence identity to amino acids 1 to 168 or amino acids 19-168 of the amino acid sequence of SEQ ID NO: 2, wherein said protein comprises six cysteine residues that are spaced relative to each other at a distance of 32 amino acids apart, 62 amino acids apart, 28 amino acids apart, 1 amino acid apart and 21 amino acids apart as arranged from the amino terminus to the carboxyl terminus of the sequence according to amino acids 1 to 168 of the amino acid sequence of SEQ ID NO: 2, wherein said protein inhibits cleavage of C5 by classical and alternative C5 convertases; or d) a fragment of the complement inhibitor polypeptide of amino acids 19 to 168 of the amino acid sequence of SEQ ID NO: 2, wherein said fragment comprises six cysteine residues that are spaced relative to each other at a distance of 32 amino acids apart, 62 amino acids apart, 28 amino acids apart, 1 amino acid apart and 21 amino acids apart as arranged from the amino terminus to the carboxyl terminus of the sequence according to amino acids 1 to 168 of the amino acid sequence of SEQ ID NO: 2, wherein said fragment inhibits cleavage of C5 by classical and alternative C5 convertases.